(Q34626479)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Interferon in the treatment of chronic hepatitis C: a drug caught between past and future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Elena Vezali

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Massimo Colombo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

21 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

301-313

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250869%20AND%20SRC:MED&resulttype=core&format=json

The global burden of hepatitis C

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

The type I interferon receptor: structure, function, and evolution of a family business.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

The IFN gamma receptor: a paradigm for cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Type III IFNs: new layers of complexity in innate antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Viruses and interferon: a fight for supremacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Current and future concepts in hepatitis C therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Actions of cytokines on the immune response and viral interactions: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Review article: pegylated interferons: chemical and clinical differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Predictors of response of US veterans to treatment for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

American Gastroenterological Association technical review on the management of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Interferon lambda as a potential new therapeutic for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

A target on the move: innate and adaptive immune escape strategies of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

21 January 2018

Cyclophilin inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906

PEG IFN alfa-2a vs. alfa-2b: And the winner is …?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.552906